Form 4 for VRTX Vertex Pharmaceuticals
Accepted 2026-07-23 16:13:11 ET · period of report 2026-07-21 · accession 0000875320-26-000251 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-07-23 16:13 | 2026-07-21 | VRTX | Sachdev Amit | EVP Chief Patient, Ext Af Off | A - Grant | $0.00 | +8,251 | 66.5K | +14% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-07-21 | A | A | 8,251 | $0.00 | 66,512 | D | — | — | (F1) Restricted stock unit award that vests on 03/31/2030. |